Device Trial Radar · NCT05741398
Evaluation of Optical System in the Treatment of - Dry Eye Disease
Last checked: Nov 20, 2026Latest source record: Jun 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
15
Planned (sponsor's estimate)
Start
Jun 1, 2023
Primary completion
Nov 1, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Demaod LtdNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 23, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Single-center, Prospective, Open Label, with Before-After Study Design, to evaluate the safety and efficacy of the optical system in the treatment of dry eye disease.
Conditions
- Dry Eye Syndromes
Interventions
VR system by DemaodDevice
non-invasive light pulse generated by a non-contacting device for the treatment of the symptoms of dry eyes and MDG
Primary outcomes
What the sponsor says the trial is designed to measure.
- 4 weeks TBUT change from baselineTime frame: up to 4 weeks post last treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Haemek Medical Center
Afula, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.